Dr. Reddy’s Laboratories (NYSE: RDY) announced yesterday that it has
launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 mL For
Subcutaneous Use, a therapeutic equivalent generic version of IMITREX
STATdose Pen® (sumatriptan succinate) 6 mg/0.5 mL
in the US market on February 25, 2014, following the approval by the
United States Food & Drug Administration (USFDA).
The IMITREX STATdose Pen® (sumatriptan succinate)
brand and generic combined had U.S. sales of approximately $169 Million
MAT for the most recent twelve months ending in December 2013 according
to IMS Health*.
Dr. Reddy’s Sumatriptan Injection USP, Autoinjector System 6 mg/ 0.5 mL
is available in a carton containing 2 single-dose prefilled syringes.
Disclaimer
This press release includes forward-looking statements, as defined in
the U.S. Private Securities Litigation Reform Act of 1995. We have based
these forward-looking statements on our current expectations and
projections about future events. Such statements involve known and
unknown risks, uncertainties and other factors that may cause actual
results to differ materially. Such factors include, but are not limited
to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand
for our products, our growth and expansion, technological change and our
exposure to market risks. By their nature, these expectations and
projections are only estimates and could be materially different from
actual results in the future.
About Dr. Reddy's
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses -
Pharmaceutical Services and Active Ingredients, Global Generics and
Proprietary Products – Dr. Reddy’s offers a portfolio of products and
services including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Major therapeutic focus is
on gastro-intestinal, cardiovascular, diabetology, oncology, pain
management and anti-infective. Major markets include India, USA,
Russia-CIS and Europe apart from other select geographies within
Emerging Markets.
IMITREX STATdose Pen® is a registered trademark of
Glaxo Group Limited
*IMS National Sales Perspectives: Retail and
Non-Retail MAT December 2013
Copyright Business Wire 2014